FOXO4-DRI (FOXO4-D-Retro-Inverso) record · updated 7h ago
FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic peptide designed as a senolytic agent, targeting the interaction between FOXO4 and p53 to induce selective apoptosis in senescent cells. The mechanism of action involves disrupting the FOXO4-p53 complex, which is crucial for maintaining cellular senescence. By inhibiting this interaction, FOXO4-DRI promotes the death of senescent cells, potentially alleviating age-related pathologies and improving tissue function.
How it works: Disrupts FOXO4-p53 complex to induce apoptosis in senescent cells
Development stage
where FOXO4-DRI (FOXO4-D-Retro-Inverso) sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.
Mass and formula from PubChem CID 167312269. No verified residue count for this compound.
| Study | Type | Year | Summary depth |
|---|---|---|---|
| Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. FindingNot reported in abstract. | Human | 2023 | Full text read0.80 |
| Neoagarotetraose from Marine Red Algae Attenuates Hypertensive Vascular Remodeling by Targeting FoxO4 to Inhibit Mitochondrial Superoxide Generation. FindingNA4 lowered blood pressure in SHR after 4 weeks of oral administration at doses of 200 or 250 mg/kg/day. | Animal | — | Full text read0.70 |
| FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. FindingNot reported in abstract. | review | 2023 | Full text read0.80 |
| FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential. TakeawayFOXO transcription factors play diverse roles in neurodegenerative diseases, but effective therapies targeting these pathways are still in early development stages. | review | 2026 | Full text read0.70 |
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching FOXO4-DRI (FOXO4-D-Retro-Inverso) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.
Articles mentioning FOXO4-DRI (FOXO4-D-Retro-Inverso)
- Anti-Aging Peptide Stack: What the Evidence Actually SupportsMost 'anti-aging peptide stacks' over-promise. Here's a defensible combination — NAD+, GHK-Cu, Epitalon, SS-31 — with what each does, what the evidence supports, and what's speculative.stack · 6 min
- Best Peptides for Anti-Aging: Evidence-Backed RankingThe peptides with the strongest evidence for aging-related endpoints — Epitalon, NAD+, GHK-Cu, SS-31, FOXO4-DRI — with what each does and realistic expectations.roundup · 4 min